Caribou Biosciences, Inc. (NASDAQ:CRBU) CFO Purchases $24,651.20 in Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) CFO Sriram Ryali acquired 17,360 shares of the firm’s stock in a transaction on Wednesday, January 29th. The stock was purchased at an average cost of $1.42 per share, with a total value of $24,651.20. Following the purchase, the chief financial officer now owns 17,360 shares of the company’s stock, valued at $24,651.20. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Caribou Biosciences Stock Up 9.2 %

Shares of NASDAQ CRBU opened at $1.43 on Friday. Caribou Biosciences, Inc. has a twelve month low of $1.30 and a twelve month high of $8.33. The firm has a market cap of $129.49 million, a PE ratio of -0.87 and a beta of 2.34. The business has a fifty day simple moving average of $1.77 and a two-hundred day simple moving average of $1.98.

Caribou Biosciences (NASDAQ:CRBU) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The firm had revenue of $2.02 million during the quarter, compared to the consensus estimate of $3.37 million. On average, research analysts expect that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on CRBU. Bank of America reduced their price target on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a research report on Friday, November 15th. Finally, Citigroup cut their price target on shares of Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, November 26th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $10.33.

Institutional Investors Weigh In On Caribou Biosciences

Hedge funds have recently modified their holdings of the business. American Century Companies Inc. boosted its position in Caribou Biosciences by 15.2% during the 2nd quarter. American Century Companies Inc. now owns 125,029 shares of the company’s stock valued at $205,000 after acquiring an additional 16,530 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Caribou Biosciences by 25.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,623,283 shares of the company’s stock worth $4,302,000 after purchasing an additional 536,162 shares during the last quarter. Renaissance Technologies LLC bought a new stake in Caribou Biosciences during the second quarter valued at about $2,432,000. Hsbc Holdings PLC grew its stake in Caribou Biosciences by 476.4% in the second quarter. Hsbc Holdings PLC now owns 80,867 shares of the company’s stock valued at $129,000 after purchasing an additional 66,838 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Caribou Biosciences in the second quarter worth about $30,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.